Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Vatalanib may be effective in preventing the development of leukemia in patients
who have myelodysplastic syndromes.
PURPOSE: This phase II trial is studying vatalanib to see how well it works in treating
patients with primary or secondary myelodysplastic syndromes.